

APPLICANTS: Ward *et al.*
SERIAL NO: 10/719,370

DOCKET NO: PTS-0070US.P1 (ISIS.038CP1)

AMENDMENTS TO THE CLAIMS: This listing of claims replaces all prior versions and listings of claims in the instant patent application.

RECEIVED
CENTRAL FAX CENTER
SEP 27 2006

Listing of claims:

1. (Currently amended) ~~A compound 12 to 50~~ An antisense oligonucleotide 15 to 30 nucleobases in length targeted to a nucleic acid molecule encoding HIF1 α (SEQ ID NO: 133), wherein said compound comprises at least ~~an 8-nucleobase portion~~ 8 consecutive nucleobases of SEQ ID NO: 446 and ~~specifically hybridizes with said nucleic acid molecule encoding HIF1 α~~ .

2-5. (Canceled)

6. (Currently amended) The ~~compound~~ antisense oligonucleotide of claim ~~[[4]]~~ 1 comprising wherein said antisense oligonucleotide is a DNA oligonucleotide.

7. (Currently amended) The ~~compound~~ antisense oligonucleotide of claim ~~[[4]]~~ 1 comprising wherein said antisense oligonucleotide is an RNA oligonucleotide.

8. (Currently amended) The ~~compound~~ antisense oligonucleotide of claim ~~[[4]]~~ 1 comprising wherein said antisense oligonucleotide is a chimeric oligonucleotide.

9-21. (Canceled)

22. (Currently amended) The ~~compound~~ antisense oligonucleotide of claim 1 having comprising at least one modified internucleoside linkage, sugar moiety, or nucleobase.

23. (Currently amended) The ~~compound~~ antisense oligonucleotide of claim 1 having comprising at least one 2'-O-methoxyethyl sugar moiety.

24. (Currently amended) The ~~compound~~ antisense oligonucleotide of claim 1 having comprising at least one phosphorothioate internucleoside linkage.

25. (Currently amended) The ~~compound~~ antisense oligonucleotide of claim 1 having comprising at least one 5-methylcytosine.

26-32. (Canceled)

APPLICANTS: Ward *et al*
SERIAL NO: 10/719,370

DOCKET NO: PTS-0070US.P1 (ISIS.038CP1)

33. (Currently amended) A method of inhibiting the expression of HIF1 α in a cell in vitro ~~cells or tissues~~ comprising contacting said cell ~~cells or tissues~~ with the compound antisense oligonucleotide of claim 1 ~~so that expression of HIF1 α is inhibited.~~

34-36. (Canceled)

37. (Currently amended) A kit or assay device comprising the compound antisense oligonucleotide of claim 1.

38-43. (Canceled)

44. (Currently amended) A composition comprising the compound antisense oligonucleotide of claim 1 in a pharmaceutically acceptable carrier.

45-118. (Canceled)

119. (Currently amended) ~~The compound of claim 1~~ An antisense oligonucleotide with a nucleotide sequence consisting of SEQ ID NO: 446.

120. (Currently amended) The compound antisense oligonucleotide of claim 1 having 100% complementarity with the nucleic acid molecule encoding HIF1 α .

121. (Canceled)

122. (Currently amended) An antisense oligonucleotide 16, 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleobases in length targeted to a nucleic acid molecule encoding HIF1-alpha (SEQ ID NO: 133), wherein said ~~compound~~ antisense oligonucleotide has at least 80% identity with SEQ ID NO: 446.

123. (Previously presented) The antisense oligonucleotide of claim 122 which is 18, 19, 20, 21 or 22 nucleobases in length and has at least 90% identity with SEQ ID NO: 446.

124. (Previously presented) The antisense oligonucleotide of claim 123 which is 19, 20 or 21 nucleobases in length and has at least 95% identity with SEQ ID NO: 446.

125. (New) The antisense oligonucleotide of claim 119 comprising a central region of ten 2'-deoxynucleotides which is flanked on each side by five 2'-O-methoxyethyl nucleotides, wherein the internucleoside linkages of said oligonucleotide are phosphorothioate throughout the oligonucleotide and the cytidine residues are 5-methylcytidines.

APPLICANTS: Ward *et al.*
SERIAL NO: 10/719,370

DOCKET NO: PTS-0070US.P1 (ISIS.038CP1)

126. (New) A pharmaceutical composition comprising the antisense oligonucleotide of claim 125.